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Background: Most European health care systems are suffering from the impact of demographic change. In short,
aging of society is leading to higher costs of treatment per capita, while reproduction rates below 2.1 children per
woman lead to a reduced number of younger people to provide for the necessary contributions into the health
insurance system.
This research paper addresses the questions what impact the demographic development will have on one
particular spending area, what are pharmaceutical expenditure in two of Europe’s largest health care systems,
Germany and France, and what the implications are for pharmaceutical companies.
Methods: The research is based on publicly available data from German and French health ministries, the OECD,
and institutes which focus on projection of demographic development in those countries. In a first step, data was
clustered into age groups, and average spending on pharmaceuticals was allocated to that. In the second step,
these figures were extrapolated, based on the projected change in the demographic structure of the countries
from 2004 until 2050. This leads to a deeper understanding of demand for pharmaceutical products in the future
due to the demographic development as a single driving factor.
Results:
– Pharmaceutical expenses per head (patient) will grow only slightly until 2050 (0.5% p.a. in both countries).
– Demographic change alone only provides for a slowly growing market for pharmaceutical companies both in
Germany and in France, but for a relevant change in the consumption mix of pharmaceutical products, based on a
shift of relevance of different age groups.
Conclusions: Despite demographic changes pharmaceutical expenses per head (patient) and the overall
pharmaceutical markets will grow only slightly until 2050 in Germany as well as in France. Nevertheless, the aging
of society implies different challenges for pharmaceutical companies and also for the health care system.
Companies have to cope with the shift of relevance of different age groups and within the health care system new
options for financing the slowly growing expenses have to be found.
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According to the statistical projections held in 2003 by
the German and the French national institutes of statis-
tics (Statistisches Bundesamt and INSEE), both countries
are expecting considerable aging of their populations
over the next decades until 2050. This demographic
change is inevitable although the forecast is more severe
in Germany than in France. As a result of the persistent
low fertility rates in Germany (less than 1.4 children per
woman in 2003), the demographic structure of the
population will change from a pyramid to a more
balanced structure during the next decades. The current
average ratio of 3:1 (people below 60 and people above
60) will change to 2:1 or even 1:1 during the following
30–50 years from 2004 according to the different scenar-
ios of demographic aging [1-3].
In France, fertility rates are higher (1.9 children per
woman in 2003) and the average fertility rate for the
years between 1988 and 2003 has been 1.8 [4]. There-
fore, the French population is also aging but the process
is slower which means that the pyramid structure per-
sists longer than in Germany.
The impact of demographic aging on social security,
health care, pensions, education and unemployment is
on the agenda of all European countries [5,6]. As med-
ical consumption increases with age, the change in the
demographic structure towards a larger group of older
people suggests an increase of the medical costs [7-10].
This research paper analyzes the pharmaco-economic
impact of demographic aging by taking into account
only one medical spending area: pharmaceutical
expenses. Isolating one cost-driving factor leads to a
deeper understanding of how the demand for pharma-
ceutical products is likely to develop prospectively in
two of Europe’s largest health care systems, Germany
and France, based on the changes in the demographic
structure and size of the population, and what the impli-
cations are for pharmaceutical companies. Hence, this
research paper explicitly excludes other factors such as
medical progress and a change in consumptive behavior
for pharmaceutical products, but focuses solely on the
impact of the change in demographic structures.
As pointed out before, Germany and France have relevant
different demographic projections in terms of speed of the
aging process and change of the size of population. A com-
parative analysis of these two countries helps to understand
the impact of the demographic component on pharmaceut-
ical expenditure in two different environments.
Methods
This research is based on publicly available data from
German and French health ministries, the OECD, and
institutes which focus on the projection of demographic
developments in those countries.In both countries, demographic projections until 2050
were published in 2003 and so 2004 was set as the consist-
ent reference year. In both projections different scenarios
were proposed. The German scenario employed in this
model has the following assumptions: a low mortality rate,
a fertility rate of 1.4 and a net migration level of 200.000
per year [1]. This corresponds to the widely spread hy-
pothesis that the fertility rate observed in the last 20 years
before 2003 will maintain unchanged in the future, mor-
tality will stay low as the average life expectancy has
grown steadily during the last decades and migration has
the tendency to be more important than today [11].
The French scenario (France without overseas col-
onies) runs under the assumptions of a low mortality
rate, a fertility rate of 2.1 and a net migration level of
100.000 per year [4]. As the French fertility rate has been
between 1.8 and 2.1 since 1980 [12,13], the authors as-
sume that higher fertility will persist until 2050. The
mortality rate is as low as in the German scenario, and
the migration effect corresponds in France as well as in
Germany to the highest projection made by the national
institutes of statistics.
In the context of this paper pharmaceutical expend-
iture refers to turnovers with drugs that were prescribed
by physicians in a considered period. Data on pharma-
ceutical expenses in Germany is based on an analysis of
the overall pharmaceutical costs per age held in 2004 for
the whole statutory health insurance system which cov-
ers 90% of the German population [14,15]. Data on
pharmaceutical expenses in France relies on an analysis
of the average pharmaceutical costs per head in 1997 of
a representative group sample in the French social se-
curity system, which covers nearly 100% of the popula-
tion [16,17]. As pharmaceutical expenses in France are
higher than in Germany since 1970 in terms of price
and volume [18-21], and since the focus of this research
lies on analyzing the impact of the demographic struc-
ture over time, the slight difference of the reference date
for the data (1997 for France and 2004 for Germany) is
considered negligible in this model.
Overall the statistical analysis for this research paper is
based on publicly available data which were used for cal-
culations with Microsoft Excel. Data for the projected
change in the demographic structure (2004–2050) and
for average spending on pharmaceuticals in Germany
and France (reference year) were provided by the already
mentioned institutes or organizations. So predicted fig-
ures for changes in population and weights of age
groups were given. Based on this, data for average
spending on pharmaceuticals could be extrapolated by
weighting data for the reference year and for 2050 with
the corresponding weight of age groups in that year.
In a last step figures for 2004 and for 2050 were com-
pared and a growth rate was calculated.
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The model is based on an analysis of the impact of
demographic change, analyzing the demographic effect
as the only driving factor for pharmaceutical expenses
until 2050. All other influences on pharmaceutical
spending as medical progress as well as behavioral
aspects of drug consumption are not taken into account.
This approach enables us to analyze the impact of one
single cost-driving factor and provides deeper insight
into the sensitivity of data on this particular component.
It also helps to clarify the notion of an aging society
hanging over all public spending areas like a sword of
Damocles as pointed out in many knowledgeable publi-
cations [5,22]. This means that it deliberately neglects
other factors that might influence the development of
pharmaceutical expenditure until 2050, and therefore
does not reflect the true overall development of pharma-
ceutical expenses, but the effect of demographic change
as one single cost-driving factor.
Step 1 Clustering data into age groups
In order to be able to allocate and extrapolate
data for pharmaceutical expenses in Germany
and France within comparable age groups, we
clustered information into age groups of 10
years, which is based on the availability of the
required information. Thus, nine clusters were
created (0–9, 10–19, 20–29, 30–39, 40–49,
50–59, 60–69, 70–79 and above 79 years of age)
which incorporate the total population – male
and female – within the age group per country
for the years 2004 and 2050 respectively.
The same approach was applied to the average
pharmaceutical expenses per head. This enables
the projection of expenses per age cluster over
time, based purely on the change in the
demographic structure of the countries.Step 2 Projecting expenses
In the second step, the total population per
country within the clusters is converted into
the relative percentage of population within the
respective cluster, in order to enable us to
reflect the relative importance of that age group
in 2004 as well as 2050. Pharmaceutical
expenses, on the other hand, remain the same.
This is done to isolate the effect of
demographic change alone, under the
assumption that we do not change the
pharmaceutical “treatment” of the population
within each age group. Therefore, this approach
enables us to identify the true impact of
demographic change alone on the development
of pharmaceuticals, based on two different
demographic developments.Pharmaceutical expenses per age group are then
multiplied with the relative weight of that
respective age group in 2004 and 2050
respectively, in the purpose of understanding the
change within each age group, as well as the
total expenses in that year.
The data and the analysis for Germany are
shown in detail in the Tables 1 and 2, for France
in the Tables 3 and 4 respectively.Results
The analysis shows that the change in the demographic
structure of both countries is not a relevant driver of
costs of pharmaceutical expenses per capita. The pro-
jected annualized growth of per capita expenses – based
on demographic change – is only 0.5% p.a., or approxi-
mately 25% from 2004 to 2050. The rate of change is al-
most identical for Germany and France, despite quite
relevant differences in the projected demographic
changes in both countries (i.e. fertility rates of 1.4 in
Germany as compared to 2.1 in France). This is mostly
due to the different levels of per capita expenses per age
group in the two countries. Figures 1 and 2 illustrate the
demographic structures of Germany and France in 2004
and 2050.
In detail, the results of the analysis are:
– The demographic effect on average pharmaceutical
expenses (per head) from 2004 to 2050 is low in
both countries. In Germany, the average per capita
expenses increase by 26% over 46 years. In France,
during the same period the increase is 24%. This
represents an annual increase of only 0.5%.
– The aging of society leads to a shift of costs in both
countries from the younger to the older people. The
structural change has no essential impact on the
average costs per head. In both countries,
pharmaceutical expenses are declining in the
younger segments and increasing in the older
segments. According to the respective shift in
population, Germany’s decline in the younger
segments and increase in the older segments is more
substantial than in France. This results in a
significant change of relevance of different age
groups for pharmaceutical expenses, as illustrated in
Figure 3.
– Fertility rate is the only major differentiation factor
when analyzing total pharmaceutical expenses
instead of per capita expenses. The overall volume
of pharmaceutical expenses in France grows
stronger than in Germany in consequence of a
projected increase in the population in France (60
Mio in 2004 and 75 Mio in 2050) as compared to a
projected decrease in Germany (83 Mio in 2004 and
Table 1 Data and analysis Germany, part 1















0-9 7694,90 5821,66 9,29% 7,63% 99,01 € 9,20 € 7,55 € -17,93%
10-19 9141,19 6282,01 11,04% 8,23% 106,10 € 11,72 € 8,73 € -25,45%
20-29 9725,63 7705,55 11,75% 10,10% 104,27 € 12,25 € 10,53 € -14,06%
30-39 12309,02 8878,96 14,87% 11,63% 157,36 € 23,40 € 18,31 € -21,75%
40-49 13324,47 9107,03 16,09% 11,93% 229,86 € 37,00 € 27,43 € -25,86%
50-59 10085,68 9816,77 12,18% 12,86% 409,99 € 49,95 € 52,74 € 5,58%
60-69 10385,48 10330,74 12,54% 13,54% 525,72 € 65,95 € 71,16 € 7,90%
70-79 6602,22 8448,77 7,97% 11,07% 728,26 € 58,08 € 80,62 € 38,81%
>79 3519,48 9928,30 4,25% 13,01% 781,84 € 33,24 € 101,71 € 206,00%
SUM 82788,06 76319,81 100,00% 100,00% 300,77 € 378,78 € 25,93%
Source: Own analysis based on [1,14].
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Germany will increase by 16%, as compared to 55%
in France from 2004 to 2050 [Tables 2, 4].
– Both countries will encounter a challenge in
financing these slowly growing expenses in the
future, as the ratio working population to non-
working population is decreasing due to an overall
aging in both countries. Taking the ratio of “people
between 20 and 59” versus “people below 20 and
above 59 years of age” as an approximate indicator
for the working-age population in these countries,
this ratio decreases in Germany from 1.22 in 2004
to 0.87 in 2050 which corresponds to 29%, while in
France the ratio decreases from 1.19 in 2004 to 0.79
in 2050 (34%) [Tables 2, 4].
Discussion
This analysis shows that the impact of demographic
change on per capita pharmaceutical expenses is low,
with a growth of only about 0.5% p.a. from 2004 to
2050. At first glance, this contradicts the leading opinion
that demographic change will lead to a substantial in-
crease in health care expenditures [23,24]. What appears
even more surprising is that the relevant differences in
projected fertility rates for Germany and France, 1.4 and
2.1 respectively, do not appear to make any difference atTable 2 Data and analysis Germany, part 2
2004 2050
Ratio age 20-60 / >60 1,22 0,87
Change ratio in % -28,50
Change population in % -7,81
Total Pharmaexpenses in bn EUR 24,90 28,91
Change in total expenses 16,1
Source: Own analysis based on [1,14].all. Does this mean that demographic change will not
lead to higher expenses in our health care systems, and
that the relevance of fertility rates on the health care sys-
tem is overrated?
The answer to that question is not as simple as the
results of this study may indicate. With respect to per
capita expenses for pharmaceuticals – in a scenario
where only the demographic structure changes and all
other components stay the same, especially pharmaceut-
ical costs per head for each age group – the answer to
the two questions above is yes. Demographic-induced
expenses for pharmaceuticals per capita will grow only
slightly, independent of the different fertility rate
scenarios.
However, there are four additional aspects to consider:
a) consumption / product mix changes, b) development
of overall market size, c) financing, and d) changes in
other relevant factors.
Ad a) Consumption / product mix changes
While overall expenses per capita do not change
a lot under the analyzed scenario, the changes
per age group do change quite significantly, as
shown in graphic 3. In this graphic, it can be
clearly seen that lower age groups lose weight
(more in Germany than in France, as a result of
a lower fertility rate), while higher age groups
grow of significance. Since the pharmaceutical
products used in those age groups typically differ,
the overall consumption pattern will also change,
placing a higher relevance and demand for
products that are targeted more towards the
elderly. For the pharmaceutical industry, this
results in a changed product mix, and hence
leads to a reallocation of research and
development expenditures.
Table 3 Data and analysis France, part 1















0-9 7279,22 8658,88 12,15% 11,60% 210,44 € 25,58 € 24,41 € -4,57%
10-19 7612,54 8513,59 12,71% 11,40% 143,91 € 18,29 € 16,41 € -10,28%
20-29 7643,13 8306,88 12,76% 11,13% 222,42 € 28,38 € 24,75 € -12,81%
30-39 8602,58 8583,24 14,36% 11,50% 310,69 € 44,63 € 35,72 € -19,95%
40-49 8482,64 8176,95 14,16% 10,95% 411,76 € 58,32 € 45,10 € -22,66%
50-59 7797,79 7787,49 13,02% 10,43% 770,93 € 100,37 € 80,42 € -19,88%
60-69 5198,12 7813,66 8,68% 10,47% 1084,67 € 94,14 € 113,53 € 20,59%
70-79 4611,94 7219,29 7,70% 9,67% 1592,33 € 122,61 € 153,98 € 25,58%
>79 2665,04 9594,43 4,45% 12,85% 1613,83 € 71,81 € 207,41 € 188,83%
SUM 59893,00 74654,40 100,00% 100,00% 564,13 € 701,73 € 24,39%








Boecking et al. BMC Public Health 2012, 12:894 Page 5 of 8






urce: OwWhile the per capita expenses change only
slightly at an almost identical rate between the
two countries, the overall markets develop
differently. In Germany, a lower population
(−7.8% in the projected scenario) leads to a
market decrease, which is partly offset by the
projected increase of 26% in per capita expenses,
leading to a total increase of 16% over 46 years
[Table 2]. This implies almost a stagnation of the
overall market size, based on the demographic
development alone. In France, a growing
population of projected 25%, combined with
slightly increased per capita expenses of 24%,
lead to a projected market growth of 55% over 46
years [Table 4]. While the annual growth rate is
low as well, from a macroeconomic perspective,
the implications of demographic change let the
French market appear more promising to
providers of pharmaceutical solutions.Ad c) Financing
Although expenses per head grow slightly, the
percentage of contributors to beneficiaries in
both health care systems decreases. This means
that both countries will be encountering a
challenge in financing these slowly growingData and analysis France, part 2
2004 2050
20-60 / >60 1,19 0,79
tio in % -33,87
opulation in % 24,65
maexpenses in bn EUR 33,79 52,39
total expenses 55,04
n analysis based on [4,16].expenses in the future. The ratio working
population to non-working population is
decreasing in both countries due to an overall
aging in both countries. Taking the ratio of
“people between 20 and 59” versus “people below
20 and above 59 years of age” as an approximate
indicator for the working age-population in these
countries, this ratio decreases in Germany from
1.22 in 2004 to 0.87 in 2050 which corresponds
to a decrease of contributors of approximately
29%, while in France the ratio decreases from
1.19 in 2004 to 0.79 in 2050 (34%). This implies
that either the cost of health insurance per head
needs to increase from 2004 to 2050 to finance
the implications of the change in the
demographic structure [25,26] (even more so in
France than in Germany), or that the providers
of pharmaceuticals have to find additional
payment opportunities outside the public health
insurance systems, such as marketing their
products more directly to the end-user within
existing legal restrictions.Ad d) Changes in other relevant factors
To isolate the impact of the change in the
demographic structures on pharmaceutical
expenses, this study assumed that other factors
remain constant. The results of that analysis are
stated above. In addition to the findings of this
study, there are other relevant factors such as
medical progress, a change of consumption
patterns within each age group over time [27],
new products for higher age groups, price caps
for certain products, duration of patents for new
products, the relevance of generic drugs, and
many more that can have further impact on the
overall development of pharmaceutical expenses



















Figure 1 Demographic structure of Germany and France in 2004 [1,4].
Figure
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led to growth rates that were significantly higher
than those resulting from demographic change
alone [23,31]. This implies that the development
of pharmaceutical expenses is more dependent
on those other factors, than on demographic
change (fertility, mortality and migration rates).With respect to demographic change alone, the

















2 Projected demographic structure of Germany and France in 20– In terms of market growth, France appears to be a
more interesting market for pharmaceutical
companies in the future than Germany,
– A shift in the medical needs: Pharmaceutical
companies will have to base their research more and
more on indications aiming to help diseases of the
elderly to address the growing significance of those
age groups with respect to their product offerings,
– Price pressure leads to a growing demand for
































Figure 3 Projected change in pharmaceutical expenses per age group in Germany and France between 2004 and 2050 [14,16].
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within existing legal restrictions. Further, there
appears to be a growing need to find income sources
outside the public health care systems, such as
out-of-pocket payments from the patient or
additional private insurance [32].
Nevertheless, medical progress and behavioral factors
may boost the demand for pharmaceuticals beyond the
impact of demographic development alone.
Limitations
All the discussed findings are based on two already men-
tioned limitations. Firstly the demographic effect is con-
sidered as the only driving factor for pharmaceutical
expenses until 2050 and other effects are neglected. Sec-
ondly the reference year for the data is 2004. The rea-
sons for using 2004 as the reference year were already
described in the methods section.
Conclusions
In summary, the implications are as follows:
– Pharmaceutical expenses per head (patient) will grow
only slightly until 2050. The effect of demographic
aging on per capita expenses, both in Germany and
France, amounts to only about 0.5% p.a.
– Due to the specific consumption patterns for
pharmaceutical expenses in both countries, the
relevant differences in fertility rates between
Germany and France do not affect the projected
development of per capita expenses with respect to
demographic change.– The relevance of specific age groups changes over
time, requiring pharmaceutical companies to adapt
to a change in the mix of pharmaceutical products,
based on the different consumption patterns of
different age groups.
– Due to a population decline in Germany and an
increase in France until 2050, overall
pharmaceutical expenses will increase by 16% in
Germany and by 55% in France. While growth for
France appears significantly higher, one has to take
into account that this covers a 46-year period. This
means that demographic change alone provides
only for a slowly growing market for
pharmaceutical companies in France and in
Germany.
– However, this demand is increasingly difficult to be
financed under the current public health insurance
systems in Germany and in France because the
projected low growth in demographic-induced
expenses is accompanied by an aging society with
decreasing ratios of “contributors to beneficiaries”.
– Therefore, pharmaceutical companies will face a
need to take a role as
∘ innovator and premium brand leader in
indications for the elderly,
∘ low-cost provider for solutions in age groups with
declining relevance, and/or
∘ finding a more direct access to private customers
and private payments as the financial pressure on
overall pharmaceutical expenditure persists due to
insufficient financing possibilities of the public
health care systems.
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